Occurrence and Reproduction of the Alabama Shad, Alosa alabamae Jordan and Evermann, in the Ouachita River System of Arkansas

The anadromous Alabama shad, Alosa alabamae, has drastically declined in abundance in recent decades throughout its historic range and has previously been reported in Arkansas from only five localities. Three of those locality records are pre- 1900. Sampling by seine in the Ouachita River drainage system of southern Arkansas in July and August of 1997 and 1998 produced more than 300 juvenile A. alabamae from two localities on the Little Missouri River and four localities on the Ouachita River. One record of an adult Alabama shad, taken on 4 April1997 by an angler below Remmel Dam on the Ouachita River, was also documented. Adults apparently ascended the Ouachita River and spawned successfully in 1997 and 1998 despite the construction of four locks and dams on that river in Louisiana and Arkansas in the 1980s. The Ouachita River drainage and a few streams in east-central Missouri are currently the only known spawning areas for A. alabamae in noncoastal regions of the entire Mississippi River basin. Continued survival of the Alabama shad in Arkansas depends on protecting critical spawning and nursery habitats in the Ouachita River system from deleterious alteration and on preserving that migratory species\u27 access to those habitats

Simultaneous Exoplanet Characterization and deep wide-field imaging with a diffractive pupil telescope

High-precision astrometry can identify exoplanets and measure their orbits and masses, while coronagraphic imaging enables detailed characterization of their physical properties and atmospheric compositions through spectroscopy. In a previous paper, we showed that a diffractive pupil telescope (DPT) in space can enable sub-microarcsecond accuracy astrometric measurements from wide-field images by creating faint but sharp diffraction spikes around the bright target star. The DPT allows simultaneous astrometric measurement and coronagraphic imaging, and we discuss and quantify in this paper the scientific benefits of this combination for exoplanet science investigations: identification of exoplanets with increased sensitivity and robustness, and ability to measure planetary masses to high accuracy. We show how using both measurements to identify planets and measure their masses offers greater sensitivity and provides more reliable measurements than possible with separate missions, and therefore results in a large gain in mission efficiency. The combined measurements reliably identify potentially habitable planets in multiple systems with a few observations, while astrometry or imaging alone would require many measurements over a long time baseline. In addition, the combined measurement allows direct determination of stellar masses to percent-level accuracy, using planets as test particles. We also show that the DPT maintains the full sensitivity of the telescope for deep wide-field imaging, and is therefore compatible with simultaneous scientific observations unrelated to exoplanets. We conclude that astrometry, coronagraphy, and deep wide-field imaging can be performed simultaneously on a single telescope without significant negative impact on the performance of any of the three techniques.Comment: 15 pages, 6 figures. This second paper, following the paper describing the diffractive pupil telescope (DPT) astrometric technique, shows how simultaneous astrometry and coronagraphy observations, enabled by the DPT concept, constrain the orbital parameters and mass of exoplanet

Differential Expression of Novel Potential Regulators in Hematopoietic Stem Cells

The hematopoietic system is an invaluable model both for understanding basic developmental biology and for developing clinically relevant cell therapies. Using highly purified cells and rigorous microarray analysis we have compared the expression pattern of three of the most primitive hematopoietic subpopulations in adult mouse bone marrow: long-term hematopoietic stem cells (HSC), short-term HSC, and multipotent progenitors. All three populations are capable of differentiating into a spectrum of mature blood cells, but differ in their self-renewal and proliferative capacity. We identified numerous novel potential regulators of HSC self-renewal and proliferation that were differentially expressed between these closely related cell populations. Many of the differentially expressed transcripts fit into pathways and protein complexes not previously identified in HSC, providing evidence for new HSC regulatory units. Extending these observations to the protein level, we demonstrate expression of several of the corresponding proteins, which provide novel surface markers for HSC. We discuss the implications of our findings for HSC biology. In particular, our data suggest that cell–cell and cell–matrix interactions are major regulators of long-term HSC, and that HSC themselves play important roles in regulating their immediate microenvironment

Multi-site investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy

CYP2C19 genotype-guided antiplatelet therapy following percutaneous coronary intervention is increasingly implemented in clinical practice. However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption. In this report, we compare and contrast implementation strategies of 12 early adopters, describing solutions to common problems and initial performance metrics for each program. Key differences between programs included the test result turnaround time and timing of therapy changes which are both related to CYP2C19 testing model and platform used. Sites reported the need for new informatics infrastructure, expert clinicians such as pharmacists to interpret results, physician champions, and ongoing education. Consensus lessons learned are presented to provide a path forward for those seeking to implement similar clinical pharmacogenomics programs within their institutions. This article is protected by copyright

Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing

PURPOSE: A number of institutions have clinically implemented CYP2D6 genotyping to guide drug prescribing. We compared implementation strategies of early adopters of CYP2D6 testing, barriers faced by both early adopters and institutions in the process of implementing CYP2D6 testing, and approaches taken to overcome these barriers. METHODS: We surveyed eight early adopters of CYP2D6 genotyping and eight institutions in the process of adoption. Data were collected on testing approaches, return of results procedures, applications of genotype results, challenges faced, and lessons learned. RESULTS: Among early adopters, CYP2D6 testing was most commonly ordered to assist with opioid and antidepressant prescribing. Key differences among programs included test ordering and genotyping approaches, result reporting, and clinical decision support. However, all sites tested for copy-number variation and nine common variants, and reported results in the medical record. Most sites provided automatic consultation and had designated personnel to assist with genotype-informed therapy recommendations. Primary challenges were related to stakeholder support, CYP2D6 gene complexity, phenotype assignment, and sustainability. CONCLUSION: There are specific challenges unique to CYP2D6 testing given the complexity of the gene and its relevance to multiple medications. Consensus lessons learned may guide those interested in pursuing similar clinical pharmacogenetic programs

LSST: from Science Drivers to Reference Design and Anticipated Data Products

(Abridged) We describe here the most ambitious survey currently planned in the optical, the Large Synoptic Survey Telescope (LSST). A vast array of science will be enabled by a single wide-deep-fast sky survey, and LSST will have unique survey capability in the faint time domain. The LSST design is driven by four main science themes: probing dark energy and dark matter, taking an inventory of the Solar System, exploring the transient optical sky, and mapping the Milky Way. LSST will be a wide-field ground-based system sited at Cerro Pach\'{o}n in northern Chile. The telescope will have an 8.4 m (6.5 m effective) primary mirror, a 9.6 deg$^2$ field of view, and a 3.2 Gigapixel camera. The standard observing sequence will consist of pairs of 15-second exposures in a given field, with two such visits in each pointing in a given night. With these repeats, the LSST system is capable of imaging about 10,000 square degrees of sky in a single filter in three nights. The typical 5$\sigma$ point-source depth in a single visit in $r$ will be $\sim 24.5$ (AB). The project is in the construction phase and will begin regular survey operations by 2022. The survey area will be contained within 30,000 deg$^2$ with $\delta<+34.5^\circ$, and will be imaged multiple times in six bands, $ugrizy$, covering the wavelength range 320--1050 nm. About 90\% of the observing time will be devoted to a deep-wide-fast survey mode which will uniformly observe a 18,000 deg$^2$ region about 800 times (summed over all six bands) during the anticipated 10 years of operations, and yield a coadded map to $r\sim27.5$. The remaining 10\% of the observing time will be allocated to projects such as a Very Deep and Fast time domain survey. The goal is to make LSST data products, including a relational database of about 32 trillion observations of 40 billion objects, available to the public and scientists around the world.Comment: 57 pages, 32 color figures, version with high-resolution figures available from https://www.lsst.org/overvie

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy